Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1654
This examiner grants 51% of resolved cases
Claudia Edilma Espinosa has 53 resolved cases in Tech Center 1600 and Art Unit 1624. Her allowance rate is 50.9 percent. The median time to allowance for these cases is 1366 days. This 1366 days figure indicates that successful prosecution typically takes several years with this examiner.
The interview lift is 57.7 percent, which is very high. This indicates that interviews are a highly effective way to improve the chances of an allowance. For the 53 cases in this profile, the 57.7 percent lift suggests that direct communication is often the key to a successful outcome. Practitioners should use the 50.9 percent allowance rate as a baseline and consider the 57.7 percent lift as a primary strategy for overcoming rejections. The 1366 days median pendency highlights the need for effective tactics like interviews to move cases toward a grant. This 57.7 percent lift is a decisive factor for applicants.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17619025 | PREVOTELLA PREPARATIONS AND TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER LUNG CONDITIONS | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17609495 | Composition and Concentrate for Use in Preparation of Dialysis Solution, Corresponding Dialysis Solution and Combinations Comprising Container | Final Rejection | Fresenius Medical Care Deutschland GmbH |
| 18162927 | METHODS FOR TREATING AMBLYOPIA | Final Rejection | City University of Hong Kong |
| 17625866 | CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATING OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL DISEASE | Final Rejection | University of Utah Research Foundation |
| 17605283 | BONE-SPECIFIC COMPLEX COMPRISING BONE CELL TRANSFORMATION RECOMBINANT PROTEIN AND BONE-TARGETING MOLECULE | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18606023 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Non-Final OA | Peptilogics, Inc. |
| 17293833 | ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF | Final Rejection | LONZA SALES AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy